目的研究半乳糖化白蛋白磁性阿霉素纳米粒(Galactosed human serum Albumin Magnetic Adriamycin Nanoparticles, GAMANP)经外周静脉用药的药物毒性。探索其半数致死量,比较其与阿霉素对大鼠血液生化和外周血细胞的影响及用药后心、肝...目的研究半乳糖化白蛋白磁性阿霉素纳米粒(Galactosed human serum Albumin Magnetic Adriamycin Nanoparticles, GAMANP)经外周静脉用药的药物毒性。探索其半数致死量,比较其与阿霉素对大鼠血液生化和外周血细胞的影响及用药后心、肝、肺、肾、肠的病理表现。反复给药观察动物对该药物有无过敏反应。方法将给GAMANP的动物分为8个剂量组,每组SD大鼠10只,观察静脉给药后急性毒性试验LD50。同时设定的空白对照组和阿霉素(Adriamycin ADM)组(6组),每组10只。观察给药后各组实验大鼠的生存情况,外周血细胞的改变和血液生化及心、肝、肺、肾等脏器的病理学变化。采用Bliss法计算LD50。SPSS(11.5)统计软件统计GAMANP和阿霉素对大鼠的外周血细胞和生化指标(肝、肾功能、心肌酶学)的影响。另选同批大鼠20只分为2组,每组10只。腹腔注射GAMANP 3次后,再次皮下注射GAMANP,观察有无过敏现象发生。结果GAMANP的动物半数致死量为515.5 mg/kg(相当阿霉素22.84 mg/kg)。阿霉素半数致死量为10.38 mg/kg。前者较后者有明显的增高。同时肝、肾功能的损害和心肌酶学的改变也明显减轻。光学显微镜下的病理损害表现也明显的减轻。20只动物进行过敏实验,观察到一只动物有过敏现象。结论GAMANP是一种很好的新型改进性药物。展开更多
由美国纳米科学技术协会（American Association of Nanoscienceand Technology，AANT）、中德纳米生物技术协会（Sino-German Association of Nanobiotechnology，SGAN）、中国卫生部纳米生物技术重点实验室联合举行的“2005美国纳米...由美国纳米科学技术协会（American Association of Nanoscienceand Technology，AANT）、中德纳米生物技术协会（Sino-German Association of Nanobiotechnology，SGAN）、中国卫生部纳米生物技术重点实验室联合举行的“2005美国纳米科学技术大会”，将于2005年12月9日至12月11日，在美国内华达洲拉斯维加斯举行。展开更多
Objective:To compare the targeting effects of lactosarninated alginate(AlgNP)、polyethylene glycol - coated hydroxyapatite- poly- L- lysine nanoparticles (PLL- PCHNP)and relative nonlactosaminated ones load ed with ex...Objective:To compare the targeting effects of lactosarninated alginate(AlgNP)、polyethylene glycol - coated hydroxyapatite- poly- L- lysine nanoparticles (PLL- PCHNP)and relative nonlactosaminated ones load ed with exogenous gene on liver via peripheral intravenous route. Methods:Preparation of AlgNP based on control of gelification phenomenon of algiante by calcium ions and HA- PLLNP with collosol - gel method, both further modified with lactosaminated - poly- L - lysine synthesized by reductive lactosamination . We used pEGFPCl as the reporter gene to establish receptor- mediated and positive liver targeting nanoparticles- gene model. The potential of adsorbing DNA on nanoparticles was analysed by electrophoresis and spectrophotometer. Then different complexes were transferred into the rat's body by peripheral intravenous route and their targeting characteristics in liver were investigated by using radioisotope tracing assay. Results: PCHNP presented as needle - like particles with a diameter of 20nm by TEM and could be effectively combined with PLL. The diameter of AlgNP was 280nm. Agarpse gel electrophoresis showed both nanoparticles could effectively combine with DNA and the optimal proportion of PLLPCHNP and DNA was 30:1 (w/w); DNA mixed ratio of AlgPLL was 68.3 % by spectrophotometer. The radioactivities in liver for the two lactosaminated nanoparticles were higher than the nonlactosaminated ones. No statistic difference between AlgNP and AlgLacNP could be found . Conclusions: Lactosaminated naroparticles can target to liver more effectively by peripheral intravenous route than nonlactosaminated ones, which is closely concerned with the characteritics of the nanopartide complex.展开更多
文摘目的研究半乳糖化白蛋白磁性阿霉素纳米粒(Galactosed human serum Albumin Magnetic Adriamycin Nanoparticles, GAMANP)经外周静脉用药的药物毒性。探索其半数致死量,比较其与阿霉素对大鼠血液生化和外周血细胞的影响及用药后心、肝、肺、肾、肠的病理表现。反复给药观察动物对该药物有无过敏反应。方法将给GAMANP的动物分为8个剂量组,每组SD大鼠10只,观察静脉给药后急性毒性试验LD50。同时设定的空白对照组和阿霉素(Adriamycin ADM)组(6组),每组10只。观察给药后各组实验大鼠的生存情况,外周血细胞的改变和血液生化及心、肝、肺、肾等脏器的病理学变化。采用Bliss法计算LD50。SPSS(11.5)统计软件统计GAMANP和阿霉素对大鼠的外周血细胞和生化指标(肝、肾功能、心肌酶学)的影响。另选同批大鼠20只分为2组,每组10只。腹腔注射GAMANP 3次后,再次皮下注射GAMANP,观察有无过敏现象发生。结果GAMANP的动物半数致死量为515.5 mg/kg(相当阿霉素22.84 mg/kg)。阿霉素半数致死量为10.38 mg/kg。前者较后者有明显的增高。同时肝、肾功能的损害和心肌酶学的改变也明显减轻。光学显微镜下的病理损害表现也明显的减轻。20只动物进行过敏实验,观察到一只动物有过敏现象。结论GAMANP是一种很好的新型改进性药物。
文摘由美国纳米科学技术协会（American Association of Nanoscienceand Technology，AANT）、中德纳米生物技术协会（Sino-German Association of Nanobiotechnology，SGAN）、中国卫生部纳米生物技术重点实验室联合举行的“2005美国纳米科学技术大会”，将于2005年12月9日至12月11日，在美国内华达洲拉斯维加斯举行。
文摘Objective:To compare the targeting effects of lactosarninated alginate(AlgNP)、polyethylene glycol - coated hydroxyapatite- poly- L- lysine nanoparticles (PLL- PCHNP)and relative nonlactosaminated ones load ed with exogenous gene on liver via peripheral intravenous route. Methods:Preparation of AlgNP based on control of gelification phenomenon of algiante by calcium ions and HA- PLLNP with collosol - gel method, both further modified with lactosaminated - poly- L - lysine synthesized by reductive lactosamination . We used pEGFPCl as the reporter gene to establish receptor- mediated and positive liver targeting nanoparticles- gene model. The potential of adsorbing DNA on nanoparticles was analysed by electrophoresis and spectrophotometer. Then different complexes were transferred into the rat's body by peripheral intravenous route and their targeting characteristics in liver were investigated by using radioisotope tracing assay. Results: PCHNP presented as needle - like particles with a diameter of 20nm by TEM and could be effectively combined with PLL. The diameter of AlgNP was 280nm. Agarpse gel electrophoresis showed both nanoparticles could effectively combine with DNA and the optimal proportion of PLLPCHNP and DNA was 30:1 (w/w); DNA mixed ratio of AlgPLL was 68.3 % by spectrophotometer. The radioactivities in liver for the two lactosaminated nanoparticles were higher than the nonlactosaminated ones. No statistic difference between AlgNP and AlgLacNP could be found . Conclusions: Lactosaminated naroparticles can target to liver more effectively by peripheral intravenous route than nonlactosaminated ones, which is closely concerned with the characteritics of the nanopartide complex.
